Rain Therapeutics Investor Relations Material

Rain Oncology Inc. (formerly Rain Therapeutics Inc.) is a biotechnology company focused on developing precision oncology therapies. It targets oncogenic drivers to select patients based on the genetic profile of their tumors. The company's lead product candidate, milademetan, is an oral small-molecule inhibitor designed to block the MDM2-p53 interaction, a key pathway in many cancers. Rain Oncology is also advancing preclinical programs, including a RAD52 inhibitor aimed at exploiting synthetic lethality in certain cancer types with homologous recombination deficiencies. The company is headquartered in Newark, California, and its shares trade on the NASDAQ.